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Abstract
Background: The transmission through contacts among MSM (men who have sex with men) is one of the
dominating contributors to HIV prevalence in industrialized countries. In Amsterdam, the capital of the Netherlands,
the MSM risk group has been traced for decades. This has motivated studies which provide detailed information
about MSM’s risk behavior statistically, psychologically and sociologically. Despite the era of potent antiretroviral
therapy, the incidence of HIV among MSM increases. In the long term the contradictory effects of risk behavior and
effective therapy are still poorly understood.
Methods: Using a previously presented Complex Agent Network model, we describe steady and casual
partnerships to predict the HIV spreading among MSM. Behavior-related parameters and values, inferred from
studies on Amsterdam MSM, are fed into the model; we validate the model using historical yearly incidence data.
Subsequently, we study scenarios to assess the contradictory effects of risk behavior and effective therapy, by
varying corresponding values of parameters. Finally, we conduct quantitative analysis based on the resulting
incidence data.
Results: The simulated incidence reproduces the ACS historical incidence well and helps to predict the HIV
epidemic among MSM in Amsterdam. Our results show that in the long run the positive influence of effective
therapy can be outweighed by an increase in risk behavior of at least 30% for MSM.
Conclusion: We recommend, based on the model predictions, that lowering risk behavior is the prominent control
mechanism of HIV incidence even in the presence of effective therapy.
Background
The HIV epidemic is a global challenge and has a
destructive impact on human life and welfare. One of
the major or even dominating contributors to HIV pre-
valence in industrialized countries is the transmission
through contacts among men who have sex with men
(MSM). Particularly, in the Netherlands, MSM still
accounts for the highest incidence of Sexually Trans-
mitted Infections (STIs) including HIV [1]. In fact, the
proportion of MSM in new HIV cases recorded at the
HIV registry continued to increase from 44% in 2003 to
59% in 2006 [1,2].
Amsterdam harbors the majority of the largest MSM
risk group in the Netherlands that has been traced and
recorded for decades, providing us with detailed infor-
mation about Amsterdam MSM’s behavior characteris-
tics. The Amsterdam Cohort Study (ACS) is such a
study which has been conducted since 1984 with thou-
sands of MSM recruited.
In order to embody heterogeneous behavior such as
personal infection progressions and steady/casual part-
nership linkages, we use agent-based modeling to simu-
late the HIV spreading among MSM in Amsterdam,
based on a previously presented Complex Agent
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Network model [3]. This model helps to describe part-
nerships in detail, with (steady or casual) partnerships,
durations and frequencies of sexual actions, influencing
the HIV spreading among MSM in a well-structured in
silico population. This enables modeling realistically het-
erogeneous populations and incorporation of social
behavior data in the model. Risk behavior is of vital sig-
nificance to HIV transmission and has sparked many
psychological surveys.
Questionnaires completed by 324 MSM aged 18-34
were conducted by Davidovich et al., to assess sexual
behavior and related cognitions [4]. The results reveal,
amongst others, that unprotected anal intercourse (UAI)
is regarded as a symbol of trust and believing that the
partner desires UAI is associated with less condom use;
additionally, perceiving UAI as more gratifying was asso-
ciated with having riskier UAI. Unfortunately, beliefs of
people living with HIV about their own responsibility for
preventing HIV transmission (personal responsibility)
and their sex partners’ responsibility for protecting them-
selves (partner responsibility) are poorly understood [5].
Despite psychological and sociological reasons, the so-
called “safer sex fatigue” and excessive confidence in low
viral load further intensify the reluctance on reducing
risky behavior. Crepaz et al., concluded [6] that people’s
beliefs about Highly Active Antiretroviral Therapies
(HAART) and viral load may promote unprotected sex,
although HIV-positive patients receiving HAART did not
exhibit increased sexual risk behavior, even when therapy
achieved an undetectable viral load. In Amsterdam, the
worrying increase of STIs was investigated in studies car-
ried out by the department of AIDS research of the
municipal health service. The result indicated that the
introduction of HAART may have had an influence on
the increase of STIs and risky sexual behavior [7].
Increase in risk behavior and resurgent epidemics have
been reported post-HAART, and resurgent epidemics is
most likely caused by increasing sexual risk behavior [8].
Furthermore, low diagnosis fraction of infections may
intensify this threat, since HIV-positive men who are
unaware of their serostatus have higher risk behavior
than the aware group [9-11]. Regarding the ACS, only
40% MSM accepted HIV testing at their STI consulta-
tion, among the recently infected at the STI clinic [12].
In this study, the primary objective is to explain and
reproduce historical data and then assess the potential
influence of varying risk behavior and therapy factors,
with the aim to understand and predict the HIV spread-
ing among MSM in Amsterdam. For this we need to
combine sexual contact networks with HIV infection
dynamics and individual behavior. To the best of our
knowledge this is the first report on this combined evi-
dence-based computational epidemics model.
Methods
Modeling the HIV epidemic in Complex Agent Networks
Using a previously developed Complex Agent Network
[3], we model the HIV epidemics among MSM in
Amsterdam through a sexual contact network in which
each node represents an individual and edges represent
potentially infectious contacts. Please see Figure 2 in
[13] as a schematic illustration of virus spreading in a
network. The number of edges emanating from a node
is the degree of the node and the degree distribution is
the distribution of this quantity across the population
[14]. In this study, the degree of a node, drawn from a
specific degree distribution, is assumed to be static
while the neighboring nodes that this node links to may
change over time. There are classes of network geome-
try such as small-world, Poisson and scale-free net-
works. Since scale-free networks have been shown to be
the representative of a variety of human sexual contact
networks [15-17], we perform stochastic simulations of
the spreading of HIV in undirected scale-free networks.
The scale-free networks are characterized by a highly
skewed distribution of contacts so that most of the
nodes are weakly connected and a small number of
nodes have very high connectivity. In particular, the
degree distribution of this class of networks follows a
power law distribution, i.e., pk = Ak-g where is a normal-
ization factor. After each node is assigned with a degree
drawn from a given power law, these nodes are con-
nected at random according to the so-called configura-
tion model [18,19] with the guarantee that the sum of
all degrees is an even number and that there are no
loops (nodes connected to themselves) and multiple
edges (between two nodes).
The disease status of infected individuals is heteroge-
nous with respects to infection stages, disease durations
and infectiousness, etc., so that we can model individuals
as agents and individuals’ status transitions as internal
changes of agents. The HIV infection progression occurs
in roughly three stages: primary infection (PI), asympto-
matic period (AP) and AIDS. Regarding status transition,
for instance, infection reaches from PI to AP with a delay
of about 3 months. We assume an irreversible “negative
⇀ PI ⇀ AP ⇀ AIDS” transition order for each infection,
excluding the case that an individual with AIDS can with
the right treatment go back to the asymptomatic phase,
because in general patients are most likely diagnosed and
treated before reaching the AIDS stage. During the HIV
epidemic, each individual’s infection status is related to
temporally varying infectiousness due to the correspond-
ing different plasma HIV RNA levels. The transmission
probability across each edge depends on the status of the
two connected individuals. Therefore, the probability
with which a susceptible individual becomes infected is
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determined by the connectivity (degree) of the individual
and the infection status of his partners (neighboring
nodes) in the network. For simplicity, we assume no HIV
mutations during the course of HIV epidemic. Addition-
ally, individuals who die of AIDS will be replaced by
healthy individuals, keeping the total of MSM under
study static throughout simulations.
Our model distinguishes between steady and casual
relationships as two types of sexual relationships, which
brings different transmission probabilities that occur
across likewise steady or casual edges. Results from pre-
vious models show that the transmission dynamics of
HIV differ significantly depending on relationship type, i.
e., long steady relationships or short casual partnerships
[20]. Moreover, there are strong indications that a sub-
stantial proportion of new HIV infections occur within
steady partnerships [20,21]. Multiple sexual actions can
take place along a steady edge (within a steady relation-
ship) yearly, while only one sexual action take place
along a casual edge (within a casual partnership) yearly.
Each individual can have at most one steady partner with
whom he stays for some time. Casual partnerships can be
formed between any two individuals, but men with a
steady partner have fewer partners than single men. Even
steady partners may be involved in casual partnerships
during or between steady relationships, though they may
negotiate safety agreements to be monogamous or to
have no UAI outside the relationship. Considering two
partners with one infected and the other susceptible, the
number of sexual acts that they have within a specified
time duration, together with the infected one’s infectious-
ness and therapy effect, the susceptible one’s susceptibil-
ity, and risk behavior involving the two, determines the
transmission probability from the infected one to the sus-
ceptible one across their partnership edge (see Section
3.3 in [3] for details).
Estimating parameters
Based on the Amsterdam cohort study (ACS) and litera-
ture, we estimate the sociological, virological and medical
values and distributions of important parameters, and
these are as listed in Table 1. The ACS of HIV infection
and AIDS among MSM living in Amsterdam was
initiated in 1984 and has involved 2299 men until 2006
[22]. Of the 2299 MSM, 571 were HIV-positive at study
entry and 192 seroconverted during follow-up until the
end of 2006. Consequently, characteristics of MSM’s
behavior and surveyed yearly HIV incidence over calen-
dar years for the population are reported periodically
[23]. How parameters in Table 1 are fed into the model
and affect the infection probability between a HIV-posi-
tive and a HIV-negative is explicitly explained in Sec. 3.3
and 5.2.2 in [3]. Specifically, the infection probability per
sexual action is computed by multiplying a multi-year
statistic of transmission probability per action and several
coefficients indicating, e.g., personal infectivity reduction
due to treatment, personal infectivity increases due to
risky behavior, and reduction of transmission probability
between two steady partners if they reach a safety agree-
ment on having no contacts outside the relationship.
Designing scenarios for predicting the HIV epidemic
The model can be used to predict the HIV epidemic by
tuning the parameters related to two important factors:
therapy effectiveness and risk behavior. Ref. [3] provides
the value for the risk behavior factor in 1985-2005
among people infected and people not infected with HIV.
It is strongly believed that risk behavior decreased until
1996 because of fear of the harm of HIV. The introdction
of HAART in 1996 was associated with a slow increase in
risk behavior. To investigate the counterbalancing impact
of therapy effectiveness and risk behavior, we design sev-
eral scenarios as listed in Table 2 to tentatively predict
the HIV epidemic among a fixed number of 2299 indivi-
duals which is the total of MSM involved in ACS substu-
dies since 1984. A reference scenario uses default values
of parameters (Table 1) which remain unchanged during
the course of simulations. Prediction scenarios 1-5 are
designed based on various combinations of therapy
reduction and risk behavior factors. We perform stochas-
tic simulations of these scenarios from 1985 to 2044
(initialized according to the situation in 1984) with 1-
year time steps and compare the results of the prediction
scenarios to that of the reference scenario, with the aim
to evaluate the significance of the factors. Each simula-
tion result is an average over 30 realizations.
Results
Reference scenario
The incidence resulting from the reference scenario (RS
in Table 2) simulation (1985-2020) versus the ACS his-
torical incidence data (1985-2006) is shown in Figure 1.
The curve of the simulated incidence is fluctuating less
intensively compared to that of the ACS historical data.
This is most likely due to the fact that the ACS has traces
and records in incomprehensive populations every year
(e.g., 2 HIV positives out of 511.12 in 1988 and 5 out of
374.54 in 2002, see Table five in [23]) while we model the
HIV epidemic in a population with a fixed size of 2299.
Compared to 1.66 in 2006, the RS incidence does not
change noticeably at the time steps following 2006. For
example, the incidence increases to 1.69 in 2015 and
1.74 in 2020, and then declining to 1.63 in 2030 and
1.60 in 2040.
Model validation
To validate our model, a chi-square goodness of fit test
and a paired-sample T-test are performed, comparing
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Table 2 Scenarios for simulating the HIV epidemic among MSM in Amsterdam (factors changed since 2006)
Scenario Risk behavior factor Treatment-induced infectivity reduction factor
Reference (RS) 1.30 Moderate
Prediction 1 (P1) 1.05*1.30 Moderate
Prediction 2 (P2) 1.05*1.30 Optimistic
Prediction 3 (P3) 1.10*1.30 Optimistic
Prediction 4 (P4) 1.20*1.30 Optimistic
Prediction 5 (P5) 1.30*1.30 Optimistic
The values of parameters change from 2006 onward in the simulations of scenarios. The risk behavior factor is a multiplicative factor of the transmission
probability between two partners. For prediction scenarios, the value of the risk behavior factor is calculated by scaling the value in 2000-2005 (1.30 for both the
HIV negative and positive, see Table 2 in [3]) to account for the increase in risk behavior after 2006. For example, an increase of 5% in risk behavior is assumed
after 2006 for P1. The distributions of the moderate and optimistic treatment-induced infectivity reduction factors are listed in Table 1. All scenarios take a value
of moderate treatment-induced infectivity reduction from 1985 to 2006.
Table 1 The values or distributions of parameters (partly) for modeling the HIV epidemic
Parameter Value Description Source
Duration of steady relationships DU (1,2)
1
The duration of steady partnerships among Amsterdam
MSM is reported to have an expected value of 1.5 years.
[20]
Duration of the asymptomatic stage for the untreated ℬ
(26,0.5)2
This stage lasts 13 years for people with a failed treatment
or without any therapy.
[24,25]
Duration of the asymptomatic stage for the successfully treated ℬ
(52,0.5)
This stage lasts a mean value of 22.5 years for people with
a successful treatment. And the duration is likely increased
to a mean value of 26 years, thanks to the wide use of
HAART and the improvement in the therapy regimens.
[26-28]
Frequency of sexual actions per year between steady partners
(with infected at stage AP)
P (30)3 The frequency of either URAI or UIAI between steady
partners is 15 per year.
[20]
Frequency of sexual actions between steady partners in the first 3
months and the last 9 months, respectively (with infected at stage
PI)
P(8)
&P(22)
The PI stage lasts for about 3 months which is shorter
than the 1-year time step, so that we divide individuals’
first year of infection into two periods. Thus, the
frequencies in these two periods adds up to 30.
[20]
Transmission probability per URAI/UIAI4 act (with infected at stage
PI)
0.22/
0.044
[29-31]
Transmission probability per URAI/UIAI act (with infected at stage
AP)
0.011/
0.0022
The infected in the last 9 months of PI contribute the
same to transmission possibility per act as they do at
stage AP.
[29-31]
Reduction in risky behavior along casual partnerships for men who
have a steady partner
0.84 Men may make an agreement with his steady partner to
be monogamous or to have no UAI outside the
relationship, leading to less risky behavior.
see Sec.
2 in [20]
Moderate (default) treatment-induced infectivity reduction factor5 CU
(0.1,0.5)6
ART can moderately reduce transmission probability by 50-
90%.
[32]
Optimistic treatment-induced infectivity reduction factor CU
(0.01,0.1)
ART can optimistically reduce transmission probability by
90-100%.
[32]
Initial population size 2299 People involved in all substudies add up to 2299. [22]
The power-law degree distribution’s exponent g in this study 1.6 MSM population follows a power-law degree distribution
with a value of g in the interval between 1.5 and 2.
[17]
The power-law degree distribution’s maximum degree kmax 200 We assume so.
The fraction of vertices with a degree of 0 0.01 We assume that a small portion in a population not
having any contact.
1DU (val1, val2) is a discrete uniform distribution with val1 and val2 as the lower and upper bounds.
2 ℬ (n, p) is a binomial distribution.
3 P(l) is a Poisson distribution.
4 URAI, unprotected receptive anal intercourse; UIAI, unprotected insertive anal intercourse.
5 Those who are receiving treatment can obtain an reduction in infectivity and thus decrease transmission probability per act. For example, 0.3 means a
reduction of 70% and 0.055 a reduction of 94.5%. The untreated’s infectivity remains on baseline quantities given in [29-31].
6 CU (val1, val2) is a continuous uniform distribution with val1 and val2 as the lower and upper bounds.
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the simulated incidence of RS and the ACS historical
incidence in 1985-2006. The null-hypothesis under con-
sideration is that there is no difference between these
two series of data with a significance level of 0.05 (data
not shown). Meanwhile, we believe that the resulting
validity also applies to the testing for all the prediction
scenarios that share identical parameter setting to that
of RS in the range of years of 1985-2006 (see Figure 2).
Prediction scenarios
The incidence resulting from prediction scenarios,
together with the RS incidence and ACS historical inci-
dence, is shown in Figure 2 and Figure 3. To further
compare these data and assess the effect of parameter
tuning, we list the simulated incidence (see Figure 3)
and the corresponding increase or decline percentage in
each specified year in Table 3. Arrows indicate the per-
centage-wise increase or decrease of simulated incidence
resulting from the prediction scenarios, compared to
that resulting from the reference scenario.
The P1 incidence is higher in each specified year than
the RS incidence though a moderate treatment-induced
infectivity reduction factor is adopted in both simula-
tions. We observe an increases of 10.95% in 2030 and of
2.87% in 2040, respectively.
Once the optimistic therapy is adopted in the follow-
ing P2-P4 simulations, the resulting incidence shows an
obvious overall downtrend compared to the RS inci-
dence, since down arrows are predominantly present in
the P2, P3 and P4 columns of Table 3. Among incidence
resulting from these 3 simulations, the P2 incidence
declines to the largest extent, e.g., by 11.24% in 2030
and 28.7% in 2040.
Surprisingly, for the P5 simulation an overall uptrend
occurs compared to the RS incidence, since up arrows
are predominantly present in the P5 column of Table 3.
Although the optimistic treatment-induced infectivity
reduction factor is used for all P2-P5 simulations, the
P5 incidence shows a totally different upgoing trend
compared to the largely downgoing incidence resulting
from the P2, P3 and P4 simulations in the long run. For
example, in 2035 there is a 5.5%↑ for P5 incidence,
while there are 26.3%↓, 10.7%↓ and 9.63%↓ for P2, P3
and P4 incidence, respectively. Additionally, from 2030
onward the P5 incidence approximately remains more
or less at the same level as the RS incidence, for
instance, 1.64 versus 1.63 in 2030 and 1.58 versus 1.60
in 2040, respectively.
In addition, the yearly fraction of the diagnosed (the
number of the diagnosed divided by the number of the
infected), inferred from our simulated results, is fluctu-
ating within the range of 0.35-0.56 and finally approach-
ing 0.41 (data not shown).
Discussion
We construct an agent-based probabilistic Complex
Agent Network model to gain increased insight into the
spread of HIV among men who have sex with men in
Amsterdam. In our approach, the in silico population is
mimicked as sexual contact networks and the transmis-
sion dynamics of HIV is embedded in those networks
describing complex interactions among MSM. Sexual
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Figure 1 The incidence resulting from the RS simulation (solid) versus the ACS historical incidence data (dashed). The RS is simulated
using default parameter values (Table 1) that remain unchanged throughout.
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contacts, steady or casual, between each pair of partners
that have individual disease status, contribute to virus
transmission from the infected to the susceptible. The
simulated incidence in 1985-2006 is able to reproduce
the ACS historical incidence well (Figure 1 and Figure
2), based on the null-hypothesis T-test performed. We
examine how two factors of vital significance-the treat-
ment-induced infectivity reduction factor and risk beha-
vior factor-influence the HIV spreading by performing a
set of scenario simulations. The resulting analyses
(Table 3) reveal that in the long term the effects of the
optimistic therapy can be counterbalanced by an
increase in risk behavior of at least 30% for MSM. This
is in line with the conclusion drawn by Wilson et al.,
that the risk of HIV transmission in male homosexual
partnerships is high over repeated exposures even in the
presence of effective treatment [33].
Our research takes advantage of the statistical details
of MSM’s behavior obtained from the ACS, showing a
promising way of simulating HIV spreading among a
specific group of people. In contrast, many other model-
ing studies were not able to incorporate this kind of
detailed data. This study provides an alternative and
reliable approach to model virus spreading in a highly
connected population with individual details. The yearly
fraction of the diagnosed is relatively low, restricting the
positive influence of highly effective therapy. This low
value is consistent with what has been observed in rea-
lity. For example, Xiridou et al., stated that 42% of the
infected people at the asymptomatic stage know they
are HIV positive (diagnosed) [20]; Gras et al., concluded
that observed annual proportions of diagnoses for
homosexual men were decreasing from about 57% in
1996 to 42% in 2004 taking into account all data in
1996-2004, or approximately remaining at 44% taking
into account data in 2000-2004 [34]. Accordingly, many
infected people are unaware of their infection due to
low fraction of diagnosis and thereby will not benefit
from highly effective therapy. Extreme preventive mea-
sures have been proposed such as universal testing fol-
lowed by immediate treatment [35]. But this approach is
not practical, as annual universal testing is a logistical
challenge and immediate treatment regardless of CD4
count is not in line with current treatment guidelines.
Policy makers therefore consider much more subtle and
realistic countermeasures.
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Figure 2 The simulated incidence of the scenarios (1985-2020) and the ACS historical incidence (1985-2006).
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The simulations demonstrates that the incidence var-
ies in different time points (Figure 2 and Figure 3). We
believe that this sort of rapid fluctuations in incidence is
inherent and is likely the result of network structures in
combination with the stochastic nature of the models.
More precise data is needed to estimate the infectious-
ness of people who are receiving therapy, taking into
consideration their adherence, behavior changes since
receiving therapy and rates of resistance emergence.
Also, a better model of estimating risk behavior is
expected to further improve our understanding of the
underlying determinants of risk behavior. For example,
the fraction of MSM that use condoms without any
exception or only during the last insertive anal inter-
course can be introduced.
The transmission model has several challenges. Firstly,
the model is validated by comparing the simulated
yearly incidence to the ACS historical incidence, ignor-
ing prevalence and other indicators. This is mainly due
to the availability of the ACS incidence data, and also
the the dimensionless feature of the incidence since the
number of recruited MSM in the ACS varies each year
while the network size remains constant throughout. To
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Figure 3 The simulated incidence of the scenarios (2005-2044).
Table 3 Resulting incidence from simulations of scenarios
Year Simulated incidence
RS* P1 P2 P3 P4 P5
2010 1.61423 1.76164 1.62148 1.7568 1.8583 2.18211
- 9.13% ↑ 0.45% ↑ 8.83% ↑ 15.12% ↑ 35.18% ↑
2015 1.69397 1.77855 1.68189 1.75922 1.87763 2.15311
- 4.99% ↑ 0.71% ↓ 3.85% ↑ 10.84% ↑ 27.1% ↑
2020 1.73505 1.79063 1.50065 1.56831 1.84138 2.0057
- 3.2% ↑ 13.51% ↓ 9.61% ↓ 6.13% ↑ 15.6% ↑
2025 1.60215 1.77855 1.54657 1.57556 1.59248 1.71331
- 11.01% ↑ 3.47% ↓ 1.66% ↓ 0.6% ↓ 6.94% ↑
2030 1.63356 1.81238 1.44991 1.40399 1.52482 1.64081
- 10.95% ↑ 11.24% ↓ 14.05% ↓ 6.66% ↓ 0.44% ↑
2035 1.5804 1.76647 1.16476 1.41124 1.42816 1.66739
- 11.77% ↑ 26.3% ↓ 10.7% ↓ 9.63% ↓ 5.5% ↑
2040 1.59973 1.64564 1.14059 1.3025 1.37016 1.57556
- 2.87% ↑ 28.7% ↓ 18.58% ↓ 14.35% ↓ 1.51%↓
Data points of incidence, taken at 5-year intervals after 2005 from the results
of scenarios simulations, are listed and compared. In each year the incidence
resulting from every prediction scenario is compared percentagewise to that
of the reference scenario (*), respectively.
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avoid a possible bias resulting from this incidence-biased
process, we can supplement comparisons according to
indicators other than incidence.
Secondly, for practicability, we assume that HAART can
to an optimistic extent reduce patients’ infectiousness by
up to 99% instead of 100%. There exists a serious contro-
versy on the effectiveness of HAART. Although HAART
could reduce viral load to an undetectable level, Edwin J
Bernard stated that being undetectable does not necessa-
rily mean being entirely uninfectious [36]. Additionally,
quantifying the proportion of people who will reach unde-
tectable viral load due to therapy still relies on further clin-
ical surveillance and statistics.
The advantages of using the Complex Agent Net-
work model have not been fully exploited in this study;
for example we use neither an individually dynamic
risk behavior factor nor consider individual histories of
risky contact (due to the lack of data). Incorporating
more data-driven details may result in dramatic
increases in computational cost to which modeling a
population in hierarchical networks can be a promising
solution [37].
Conclusion
Our results suggest that the positive influence of effec-
tive therapy can be outweighed by an increase in risk
behavior of at least 30% for MSM. This implies that if
universal voluntary HIV testing is currently impossible
or impractical, lowering risk behavior is the prominent
control mechanism of HIV incidence even in the pre-
sence of effective treatment. This is an essential result
since recent studies indicate that even in the presence of
potent antiretroviral therapy, the incidence of HIV
among MSM still increases.
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